• Sulforaphane Workflows for Redox and Inflammation

  2026-08-26

  Build reproducible Sulforaphane workflows that connect Keap1–Nrf2 signaling, oxidative stress, cell-cycle control, apoptosis, and NLRP3 inflammasome biology. This guide translates cell and mouse evidence into practical dose selection, orthogonal readouts, and troubleshooting strategies for cancer chemoprevention and inflammatory disease research.

• ATF4, H2S, and Doxorubicin Cardiomyopathy

  2026-08-26

  This preprint identifies an ATF4–CSE–H2S pathway that limits oxidative stress and apoptosis during doxorubicin-induced cardiomyopathy. Using genetic loss- and gain-of-function models, RNA-seq, chromatin immunoprecipitation, reporter assays, and rescue experiments, the study connects KLF16 suppression with impaired cardiac antioxidant defense.

• Azilsartan (TAK-536): From AT1 Blockade to Translation

  2026-08-25

  A mechanistic guide to using Azilsartan as a causal AT1 receptor probe across cardiovascular, renin–angiotensin system, and astrocyte–microglia inflammation research.

• Y-27632 in Barrier Biology: A Mechanistic Guide

  2026-08-25

  Explore how Y-27632, a selective ROCK inhibitor, can clarify cytoskeletal contributions in epithelial barrier assays. This guide connects ROCK perturbation with the immune–epithelial findings of recent Treg IL-6R research while separating established evidence from experimental hypotheses.

• HFM1 Mutation Disrupts Zygotic Genome Activation

  2026-08-24

  A case-based study links a homozygous HFM1 variant to aberrant mRNA splicing, defective nuclear localization, failed zygotic genome activation, and preimplantation embryo arrest. The work combines patient-embryo molecular analysis with mouse embryo rescue experiments, while its single-case design calls for validation in larger cohorts.

• How Drug-Response Metrics Improve Cancer Models

  2026-08-23

  Hannah Schwartz’s 2022 dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a clearer framework for separating growth inhibition from cell killing, improving the interpretation and design of in vitro drug-response experiments.

• Cyanin Chloride in a HaCaT Psoriasis Model

  2026-08-22

  The 2024 reference study links cyanin chloride with radical-scavenging activity, reduced inflammatory signaling, STAT3 regulation, and improved barrier-associated responses in cell-based psoriasis models. Its main value is the integrated assessment of inflammation and epidermal barrier function, while its in vitro design requires cautious interpretation before clinical or therapeutic conclusions.

• EZ Cap™ Firefly Luciferase mRNA Workflow Guide

  2026-08-21

  Build sensitive reporter workflows around Cap1-capped, polyadenylated luciferase mRNA for delivery screening, gene regulation studies, and in vivo bioluminescence imaging. This guide connects practical handling and assay design with lipid nanoparticle size insights that can improve reproducibility without confusing formulation effects with biological effects.

• Mechanism to Translation with HotStart qPCR

  2026-08-21

  A translational framework for using SYBR Green qPCR to connect Nrf2 and EGFR/PI3K/AKT biology with reproducible molecular evidence in PM2.5-related COPD research.

• S1P Signaling: From Vascular Biology to Apoptosis

  2026-08-20

  Sphingosine-1-phosphate is more than a vascular signaling reagent: it is a receptor-contextual probe for linking endothelial behavior, cell survival, inflammation, and neuronal apoptosis. This translational guide explains how to use S1P with receptor-aware controls, fresh-solution handling, orthogonal readouts, and evidence from acute intracerebral hemorrhage research.

• Phosbind Acrylamide for Protein Phosphorylation Analysis

  2026-08-20

  Phosbind Acrylamide adds phosphate-sensitive mobility analysis to familiar SDS-PAGE workflows, helping researchers compare phosphorylation states without phospho-specific antibodies. Its most useful applications include plant signaling studies, kinase assays, and carefully controlled extensions into pathways such as caspase signaling.

• CHK1 Inhibition in Breast Cancer: ER/PR Context

  2026-08-19

  The 2020 study by Xu and colleagues shows that CHK1 inhibition does not produce a uniform response across breast cancer subtypes. Its effects on doxorubicin sensitivity and single-agent growth control depend on ER/PR status, with distinct roles for the MCC–APC/C–cyclin B1, CENPF, p21, Eg5, Fas, MSX2, and BIM pathways.

• BIRB 796: Designing Better p38α Assays

  2026-08-18

  BIRB 796 (Doramapimod) offers unusually selective control of p38α signaling. This guide explains how allosteric inhibition, phosphatase-driven dephosphorylation, and assay timing should shape inflammation research, cytokine measurements, and apoptosis experiments.

• Methylprednisolone Sodium Succinate in Translation

  2026-08-18

  A translational framework for using Methylprednisolone Sodium Succinate to connect nuclear receptor-driven gene regulation with cytokine, leukocyte, tumor-cell, and functional outcomes. The article emphasizes exposure-aware assay design, acute spinal cord injury treatment research, oncology relevance, and evidence maturity while using palonosetron development as a strategic lesson in translating pharmacologic differences into meaningful endpoints.

• Fibroblast States in Airway Reconstruction Repair

  2026-08-17

  The 2025 JCI Insight study shows that airway repair after reconstruction is coordinated by spatially distinct fibroblast subsets rather than a uniform fibroblast population. Single-cell RNA sequencing links surgery-induced stress to specialized perichondrial, immune-recruiting, and Cthrc1-positive fibroblast states, offering a mechanistic framework for understanding fibrosis, stenosis, and impaired epithelial recovery.

456 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page